Multiple Sclerosis (MS) is a complex and challenging disease, but the year 2025 brought some exciting developments and breakthroughs that give us hope for the future. Let's dive into the top 5 most-read articles of 2025, which highlight the latest advancements in MS research and treatment.
Unveiling the Future of MS Care: A Glimpse into 2025
The past year has been a game-changer for MS research, with a strong focus on optimizing existing treatments and exploring new avenues to tackle the progressive forms of the disease. From confirming the optimal dosage of a leading therapy to uncovering the critical role of the Epstein-Barr virus (EBV) in MS development, researchers are revolutionizing the treatment landscape.
MS is an immune-mediated condition that damages the protective myelin covering of nerves, primarily affecting the central nervous system. Despite having over 20 FDA-approved disease-modifying therapies (DMTs), the search for effective treatments for progressive MS forms and preventive strategies continues.
Here are the top 5 MS articles that showcase critical advances and clinical insights:
5. Ongoing Clinical Trials: Unlocking New Possibilities
Researchers are tirelessly investigating various therapeutic agents to enhance our understanding and management of MS. Currently, there are 28 active clinical trials exploring DMTs like ocrelizumab, fingolimod, and ublituximab. Let's take a closer look at some notable trials:
- Tolebrutinib (NCT04742400): This phase 2 trial focuses on adults already receiving anti-CD20 therapy, aiming to assess the effectiveness of the BTK inhibitor in reducing chronically inflamed white matter lesions. Estimated completion: December 31, 2025.
- Fingolimod (NCT01892722): A phase 3, multicenter, randomized trial comparing daily oral fingolimod with weekly intramuscular interferon β-1a in pediatric patients aged 10-17 years. This trial includes a 5-year extension phase and is estimated to be completed by February 26, 2030.
- Ocrelizumab (NCT04377555): A phase 4, open-label study focusing on Black or African American and Hispanic/Latino patients with relapsing MS. The study aims to assess disease activity and biomarkers, with an estimated completion date of December 2025.
- Ublituximab (NCT04130997): An open-label extension of ULTIMATE I and II trials, evaluating the long-term safety and efficacy of ublituximab in adults with relapsing MS. The primary outcome is the annualized relapse rate, and the trial is estimated to be completed by February 1, 2030.
- Fenebrutinib (NCT04544449): The phase 3 FENtrepid trial assesses the efficacy and safety of the oral BTK inhibitor fenebrutinib against an ocrelizumab-matching placebo in adult patients with primary progressive MS. The trial focuses on the time to onset of confirmed disability progression and is estimated to be completed on December 18, 2026.
4. Higher Dose vs Approved Dose: A Surprising Finding
Ocrelizumab (Ocrevus), a B-cell therapy approved for relapsing and primary progressive MS, is the most-prescribed DMT in the US, having treated over 400,000 people globally. The phase 3 MUSETTE trial (NCT04544436) confirmed the optimal dosing strategy for this established treatment. The trial investigated whether a higher dose of IV ocrelizumab (1200 mg or 1800 mg, depending on weight) would provide additional benefits compared to the approved 600 mg dose in patients with relapsing MS. However, the trial failed to meet its primary endpoint, demonstrating no added benefit in slowing disability progression. The results showed consistent disability progression rates similar to those seen with the standard 600 mg dose, reinforcing its effectiveness. The higher dose was well-tolerated and showed no new safety concerns, further supporting ocrelizumab's strong safety and efficacy profile.
3. Real-World Data: Ocrelizumab's Adherence and Discontinuation Rates
A systematic review of real-world data provides reassuring insights into patient adherence to ocrelizumab. The analysis, including 30 studies, found that discontinuation rates ranged from 3.2% to 4.1% for patients with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). This stability suggests high tolerability outside of controlled clinical settings. The most common reasons for discontinuation were side effects, followed by concerns about efficacy and pregnancy/family planning. Discontinuation typically occurred after a median of 0.6 to 1.8 years. When compared to other DMTs, ocrelizumab demonstrated higher adherence and lower discontinuation rates, reinforcing its role as a cornerstone therapy for MS.
2. Emerging Treatments: A Ray of Hope for Progressive MS
While current MS therapies have significantly improved outcomes for relapsing forms, treating progressive MS remains a challenge. A comprehensive review of emerging therapies highlights innovative strategies focused on myelin repair, neuroprotection, and targeting CNS-resident immune cells. One promising class of drugs is Bruton tyrosine kinase inhibitors (BTKis). Tolebrutinib, a BTKi that can cross the blood-brain barrier, showed a substantial effect in slowing confirmed disability progression in individuals with nonrelapsing secondary progressive MS. BTKis are believed to act on B cells, macrophages, and microglia within the CNS, suggesting a mechanism that addresses progression independently of relapses. Other BTKis like fenebrutinib and remibrutinib also show potential in limiting lesion activity. Additionally, research is advancing remyelination and neuroprotective strategies, including investigating compounds like clemastine fumarate and metformin in combination to stimulate myelin repair. Cell therapies, such as autologous hematopoietic stem cell transplantation and mesenchymal stem cells, are also being explored for their regenerative capabilities. These efforts offer hope that future treatments may finally slow or halt disease progression and restore neurological function.
1. Targeting Epstein-Barr Virus: A New Approach to Combat MS
A growing body of evidence strongly links the Epstein-Barr virus (EBV), a common herpesvirus that causes mononucleosis, to multiple sclerosis. Epidemiological studies show that individuals who have never been infected with EBV have a near-zero risk of developing MS. A recent review supports the "driver hypothesis," suggesting that ongoing EBV replication and infection cycles continuously expose the immune system to viral antigens, fueling the inflammatory disease activity seen in MS. Researchers are now calling for a new focus in drug development, targeting EBV with CNS-penetrant small molecule antiviral agents, therapeutic EBV vaccines, and higher-dose B-cell depleting therapies. The authors recommend large-scale, long-term studies to uncover the exact mechanisms by which EBV triggers MS and autoimmunity. This targeted approach could be a game-changer in the fight against MS.
Stay tuned for more updates and insights on the latest developments in MS research and treatment. Remember, knowledge is power, and together, we can make a difference in the lives of those affected by MS.
